Draft evidence report reviewing ovarian cancer drugs

The US non-profit Institute for Clinical and Economic Review (ICER) has released a  Draft Evidence Report assessing the comparative clinical effectiveness and value of three poly ADP-ribose polymerase (PARP) inhibitors for treatment of ovarian cancer.

The three drugs covered are: Lynparza (olaparib), from AstraZeneca (LSE: AZN)); Rubraca (rucaparib), from Clovis Oncology (Nasdaq: CLVS); and Zejula (niraparib, from Tesaro (Nasdaq: TSRO). The report, along with draft voting questions, will be open to public comment for four weeks.

The ICER says it is committed to engaging with all stakeholders in a thorough and transparent manner. Before completing this Draft Evidence Report, ICER reached out to key stakeholders, including patient groups, clinical experts, and the manufacturers of the drugs to engage them in the process. ICER also accepted public comments on a Draft Scoping Document prior to conducting the review.  The current draft report incorporates input received from patients, clinicians, manufacturers, and other stakeholders during each of these opportunities for engagement.